For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 4,106 | 7,715* | 5,774 | 3,613 |
| General and administrative | 2,154 | 1,918* | 2,020 | 2,982 |
| Operating loss | -6,260 | -9,633* | -7,794 | -6,595 |
| Finance income | 210 | 243* | 332 | 261 |
| Net loss | -6,050 | -9,391* | -7,462 | -6,334 |
| Effect of warrants modification, see note 6 | - | -4,858* | 2,429 | - |
| Total net gain attributable to common shareholders | -6,050 | -4,533 | -9,891 | - |
| Basic EPS | -0.26 | -0.212 | -0.44 | -0.3 |
| Diluted EPS | -0.26 | -0.212 | -0.44 | -0.3 |
| Basic Average Shares | 23,414,475 | 21,352,823 | 22,719,057 | 21,366,268 |
| Diluted Average Shares | 23,414,475 | 21,352,823 | 22,719,057 | 21,366,268 |
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)